Renaissance Technologies’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-219,100
Closed -$460K 3557
2016
Q4
$460K Buy
219,100
+33,300
+18% +$77.7K ﹤0.01% 2787
2016
Q3
$491K Buy
185,800
+16,700
+10% +$41.7K ﹤0.01% 2819
2016
Q2
$321K Buy
169,100
+22,700
+16% +$59.7K ﹤0.01% 2928
2016
Q1
$430K Buy
146,400
+41,300
+39% +$118K ﹤0.01% 2882
2015
Q4
$328K Buy
105,100
+46,900
+81% +$160K ﹤0.01% 2861
2015
Q3
$184K Buy
58,200
+23,000
+65% +$88.5K ﹤0.01% 2914
2015
Q2
$134K Buy
+35,200
New +$135K ﹤0.01% 3058
2015
Q1
Sell
-12,549
Closed -$80K 3454
2014
Q4
$80K Sell
12,549
-25,600
-67% -$150K ﹤0.01% 2829
2014
Q3
$187K Sell
38,149
-25,600
-40% -$148K ﹤0.01% 2568
2014
Q2
$487K Buy
63,749
+26,700
+72% +$213K ﹤0.01% 2336
2014
Q1
$391K Buy
37,049
+23,100
+166% +$330K ﹤0.01% 2434
2013
Q4
$181K Buy
+13,949
New +$130K ﹤0.01% 2645
2013
Q3
Sell
-9,182
Closed -$52K 3041
2013
Q2
$52K Buy
+9,182
New +$57K ﹤0.01% 2693

Other funds holding OCRX

Renaissance Technologies's OCRX Position: Q1 2017 in Review

Renaissance Technologies sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2017, closing a stake of 219,100 shares — an estimated $460K sold.

Renaissance Technologies first reported a position in OCRX in Q2 2013 and held it in 13 quarters. The position peaked at $491K in Q3 2016. 26 funds tracked by Wall St. Rank hold OCRX as of Q1 2017.

  • Renaissance Technologies reported no remaining Ocera Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Renaissance Technologies sold 219,100 Ocera Therapeutics, Inc. shares in Q1 2017, an estimated $460K.
  • Renaissance Technologies first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
  • Renaissance Technologies's Ocera Therapeutics, Inc. position peaked at $491K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2017.

Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.